Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Want to cut your energy bills? Here’s how five experts are doing it 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
NEW YORK, March 18, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Tetraphase Pharmaceuticals Inc. (“Tetraphase”) (NASDAQ:TTPH) between March 5, 2015 and September 8, 2015. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. To get more information go to:
http://zlk.9nl.com/tetraphase-pharmaceuticals-ttph
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that Tetraphase and certain insiders issued materially false and misleading statements to investors. In particular, it is alleged that throughout the class period, Tetraphase made positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.
On September 8, 2015, the Company announced that the pivotal portion of its IGNITE2 phase 3 clinical trial of Eravacycline did not achieve its primary endpoint. Following this news, shares of Tetraphase fell from a close of $44.78 on September 8, 2015, to a close of $8.36 per share on September 10, 2015—a loss of more than 80% in market value.
If you suffered a loss in Tetraphase you have until March 28, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
